On Nov 1, The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that updates Medicare Advantage (MA or Part C) and the Medicare Prescription Drug Benefit Program (Part D).
On November 1, 2018, the Centers for Medicare & Medicaid Services (CMS) finalized its rule for the 2019 Physician Fee Schedule (PFS) and the Quality Payment Program (QPP).
Leg-Reg Briefing November 2018: Recap of Federal, State Midterm Elections; AMCP Seeks Feedback on New CMS Proposed Rules; CMS Finalizes Physician Fee Schedule for CY 2019
List of Forum topics for 2019. For additional information, contact: AMCP’s Strategic Alliances & Corporate Services Office | busdevelopment@amcp.org | (703) 684-2616
On October 30, 2018, CMS published an Advanced Notice of Proposed Rulemaking for a potential International Pricing Index (IPI) Model for Medicare Part B Drugs. The model would be phased in over a five-year period and will be tested as a pilot program through the CMS Center for Medicare and Medicaid Innovation. The model is intended to lower expenditures for Part B drugs by implementing an international reference price to shift payments to a level that is comparable with prices in other countries. It also seeks to reform the current “buy and bill” system for Part B drugs and alter reimbursement methodology to eliminate existing incentives to prescribe higher-cost drugs.
AMCP webinar that reviewed AMCP’s activity related to preapproval information exchange (PIE) and provided the payer and manufacturer perspective on the important and usefulness of PIE.